AI-assisted mole mapping is changing surveillance, not replacing examination
Skin cancer remains one of the fastest-rising cancers, and melanoma incidence in the United States has increased by approximately 150% since the early 1990s. Projected growth through 2040 adds urgency to a problem dermatology has long faced: early lesions are often silent, subtle, and easy to miss. They may not itch, hurt, or bleed, and some hide in places people rarely inspect, including under the nails, on the palms, or on the soles of the feet. In that setting, skin cancer checks depend on two linked habits — careful self-examination at home and professional surveillance when risk is higher or a lesion changes.
At an appointment using the Canfield IntelliStudio3 system at the Cadogan Clinic in London, the process centered on full-body documentation first, then closer inspection of selected moles with dermoscopy and AI-assisted imaging. The workflow took about 10 to 15 minutes for mapping and another 15 minutes for scanning. High-resolution 360-degree images were then used to document lesion features such as size, color, shape, and symmetry, with the system generating a report intended for longitudinal comparison rather than a one-time snapshot. In practical terms, the value lies in tracking small deviations over time, because melanoma often announces itself through evolution rather than dramatic appearance.
A single image can miss the story a lesion is telling.
Why change matters more than any one feature
Susan Mayou, MD, emphasized that the most important warning sign is change. A mole or lesion that shifts in size, shape, or color over weeks or months deserves assessment, especially when the change is new enough for a patient to notice. The dermatologist also pointed to the familiar ABCDE framework used to separate ordinary moles from suspicious ones: asymmetry, irregular border, uneven or multiple colors, diameter larger than 6 millimeters, and evolution over time. Those criteria are widely taught because they mirror the biology of melanoma, which often disturbs pigment patterning, distorts borders as it expands laterally, and becomes increasingly irregular as it progresses.
Yet melanoma does not always present as a dark mole. Some lesions are pink, red, or white, and that variability makes visual screening harder than many patients expect. A changing lesion that looks unlike surrounding moles can be just as concerning as one that fits the classic ABCDE pattern. Mayou also cited the “ugly duckling” sign, where one lesion stands out from a person’s other moles. That concept is clinically useful because people tend to develop a personal baseline of benign patterns over time; a lesion that breaks from that internal pattern can be easier to identify than one judged in isolation.
Other changes warranting prompt evaluation include bleeding, crusting, itching, pain, lumpiness, repeated breakdown, or a new lesion that looks distinctly different from nearby skin. Those features do not diagnose cancer on their own, but they lower the threshold for biopsy or closer follow-up because they can reflect tissue disruption, local invasion, or surface erosion.
Who needs screening earlier and more often
There is no universal age at which every person needs routine professional skin checks. For average-risk adults, familiarity with one’s own skin and regular self-examination are the main starting points. Professional assessment becomes more valuable when risk factors are present or when a lesion is new, changing, or otherwise unusual.
Several groups need closer attention. Fair skin, significant sun exposure or sunburn history, numerous moles, atypical moles, a personal or family history of melanoma, and a weakened immune system all increase concern. A prior history of skin cancer also calls for a separate follow-up plan rather than a one-size-fits-all schedule. These risk factors matter because cumulative ultraviolet injury and impaired immune surveillance both increase the chance that atypical melanocytes will progress rather than remain stable.
Darker skin does not eliminate risk. Melanoma can occur in anyone, and recognition may be harder on Black and brown skin because contrast is lower and lesions may appear in less expected sites. That makes awareness especially important for people who might otherwise assume they are protected by skin tone alone. Delayed recognition in these populations can translate into later-stage diagnosis, which is exactly where surveillance tools and education have the greatest bedside value.
Where AI fits in dermatology today
AI-assisted mole mapping has clear appeal because it strengthens longitudinal surveillance. Subtle changes that are barely visible during a brief appointment may become obvious when high-quality images are compared side by side over time. In that sense, AI functions as a memory aid for the clinician, preserving detail and flagging lesions that deserve closer attention. It is particularly useful for patients with many moles, where manual recall of every lesion becomes unrealistic.
Still, the technology is not a stand-alone answer. Mayou was explicit that AI should complement, not replace, the expertise of a dermatologist. A skin examination incorporates history, risk factors, the behavior of the lesion, the appearance of the wider mole pattern, and symptoms noticed by the patient. Image analysis alone cannot fully account for those contextual clues, and performance varies by system, image quality, lesion type, and patient characteristics.
Evidence gaps remain, especially in real-world populations and across different skin tones. NICE has reporting the need for more data on automated systems in people with Black and brown skin, and that concern is clinically important because false reassurance would be especially harmful in groups already at risk of delayed recognition. AI can sharpen surveillance, but final interpretation still belongs to a trained clinician who can decide whether a lesion should be monitored, photographed again, or removed for histology.
Home checks remain essential because they catch the changes a machine never sees between appointments. A careful monthly self-exam, paired with professional review when something looks different, remains the most practical route to earlier detection. For patients with higher risk, the combination of baseline imaging, serial comparison, and clinician judgment offers the strongest guard against a lesion that evolves quietly.